Working Paper |
File Downloads |
Abstract Views |
Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
A Retrospective Evaluation of the GDF/Suez Merger: Effects on Gas Hub Prices |
0 |
0 |
2 |
46 |
1 |
2 |
5 |
80 |
A Retrospective Study of State Aid Control in the German Broadband Market |
0 |
0 |
2 |
20 |
0 |
0 |
2 |
35 |
A Retrospective Study of State Aid Control in the German Broadband Market |
0 |
0 |
1 |
22 |
0 |
2 |
3 |
37 |
A Retrospective Study of State Aid Control in the German Broadband Market |
0 |
0 |
0 |
23 |
0 |
0 |
3 |
40 |
A retrospective evaluation of the GDF/Suez merger: Effects on gas hub prices |
0 |
0 |
0 |
55 |
0 |
1 |
7 |
63 |
Acquiring R&D Projects: Who, When, and What? Evidence from Antidiabetic Drug Development |
0 |
0 |
10 |
10 |
1 |
2 |
13 |
13 |
Acquiring R&D projects: who, when, and what? Evidence from antidiabetic drug development |
0 |
1 |
13 |
14 |
0 |
1 |
11 |
12 |
Acquiring R&D projects: who, when, and what? Evidence from antidiabetic drug development |
0 |
0 |
0 |
0 |
0 |
1 |
2 |
2 |
Collusion through Joint R&D: An Empirical Assessment |
0 |
1 |
1 |
63 |
0 |
2 |
2 |
114 |
Collusion through Joint R&D: An Empirical Assessment |
0 |
0 |
0 |
78 |
0 |
1 |
2 |
185 |
Collusion through joint R&D: An empirical assessment |
0 |
0 |
0 |
167 |
0 |
1 |
2 |
217 |
Common Ownership Patterns in the European Banking Sector – The Impact of the Financial Crisis |
1 |
1 |
2 |
8 |
1 |
1 |
2 |
10 |
Common Ownership and Market Entry: Evidence from Pharmaceutical Industry |
0 |
0 |
1 |
61 |
1 |
4 |
10 |
254 |
Common Ownership and Market Entry: Evidence from the Pharmaceutical Industry |
0 |
0 |
2 |
60 |
1 |
4 |
21 |
223 |
Common Ownership and Market Entry: Evidence from the Pharmaceutical Industry |
0 |
0 |
0 |
53 |
0 |
3 |
4 |
85 |
Common Ownership in the US Pharmaceutical Industry: A Network Analysis |
0 |
0 |
0 |
21 |
0 |
0 |
1 |
62 |
Common Ownership in the US Pharmaceutical Industry: A Network Analysis |
0 |
1 |
2 |
15 |
0 |
1 |
4 |
39 |
Common Ownership: Europe vs. the US |
0 |
0 |
0 |
5 |
1 |
1 |
3 |
8 |
Common ownership and market entry: Evidence from the pharmaceutical industry |
0 |
0 |
1 |
17 |
1 |
3 |
10 |
86 |
Common ownership and market entry: Evidence from the pharmaceutical industry |
0 |
0 |
0 |
98 |
1 |
2 |
9 |
110 |
Common ownership in the US pharmaceutical industry: A network analysis |
0 |
0 |
0 |
15 |
0 |
0 |
1 |
20 |
Common ownership in the US pharmaceutical industry: A network analysis |
0 |
0 |
1 |
13 |
0 |
0 |
1 |
30 |
Common ownership: Europe vs. the US |
0 |
0 |
0 |
5 |
0 |
1 |
3 |
15 |
Effective European Antitrust: Does EC Merger Policy Generate Deterrence |
0 |
0 |
0 |
34 |
0 |
0 |
2 |
62 |
Effective European Antitrust: Does EC Merger Policy Generate Deterrence |
0 |
0 |
1 |
44 |
0 |
0 |
3 |
66 |
Effective European antitrust: Does EC merger policy generate deterrence? |
0 |
0 |
0 |
1 |
0 |
1 |
1 |
37 |
How to Measure the Deterrence Effects of Merger Policy: Frequency or Composition? |
0 |
0 |
0 |
45 |
1 |
1 |
1 |
215 |
How to Measure the Deterrence Effects of Merger Policy: Frequency or Composition? |
0 |
0 |
0 |
57 |
0 |
0 |
0 |
163 |
Interactions Between Product and Labour Market Reforms |
0 |
0 |
0 |
283 |
0 |
0 |
11 |
1,077 |
Merger Clusters during Economic Booms |
1 |
1 |
2 |
100 |
3 |
4 |
5 |
391 |
Merger Failures |
0 |
1 |
1 |
450 |
0 |
1 |
3 |
1,325 |
Merger failures |
0 |
0 |
1 |
228 |
0 |
0 |
3 |
571 |
Mergers, Investment Decisions and Internal Organisation |
0 |
0 |
0 |
5 |
0 |
1 |
2 |
71 |
Mergers, Investment Decisions and Internal Organisation |
0 |
0 |
0 |
86 |
0 |
0 |
1 |
443 |
Mergers, Investment Decisions and Internal Organisation |
0 |
0 |
0 |
192 |
0 |
0 |
0 |
470 |
Mergers, Investment Decisions and Internal Organisation |
0 |
0 |
0 |
343 |
1 |
1 |
1 |
1,286 |
On The Stability of Research Joint Ventures: Implications for Collusion |
0 |
0 |
0 |
68 |
0 |
0 |
0 |
223 |
On the Stability of Research Joint Ventures: Implications for Collusion |
0 |
0 |
0 |
71 |
0 |
0 |
0 |
263 |
Ownership Diversification and Product Market Pricing Incentives |
0 |
0 |
0 |
17 |
0 |
0 |
3 |
39 |
Ownership Diversification and Product Market Pricing Incentives |
0 |
0 |
0 |
1 |
1 |
1 |
2 |
4 |
Ownership Diversification and Product Market Pricing Incentives |
0 |
0 |
0 |
12 |
1 |
1 |
4 |
12 |
Ownership diversification and product market pricing Incentives |
0 |
0 |
0 |
2 |
0 |
1 |
1 |
7 |
R&D Spillovers through RJV Cooperation |
0 |
0 |
0 |
5 |
0 |
0 |
3 |
12 |
R&D Spillovers through RJV Cooperation |
0 |
0 |
0 |
3 |
1 |
1 |
2 |
24 |
R&D Spillovers through RJV Cooperation |
0 |
0 |
0 |
9 |
0 |
0 |
3 |
20 |
R&D Spillovers throught RJV Cooperation |
0 |
0 |
1 |
18 |
1 |
1 |
4 |
47 |
Remedy for Now but Prohibit for Tomorrow: The Deterrence Effects of Merger Policy Tools |
0 |
0 |
1 |
69 |
0 |
0 |
2 |
276 |
Remedy for Now but Prohibit for Tomorrow: The Deterrence Effects of Merger Policy Tools |
0 |
0 |
0 |
51 |
0 |
0 |
1 |
199 |
Remedy for Now but Prohibit for Tomorrow: The Deterrence Effects of Merger Policy Tools |
0 |
0 |
1 |
48 |
0 |
0 |
1 |
193 |
Screening and Merger Activity |
0 |
0 |
0 |
91 |
0 |
1 |
2 |
355 |
The Contingent Effect of Alliance Design on Alliance Dynamics and Performance: An Experimental Study |
0 |
0 |
1 |
30 |
0 |
0 |
3 |
50 |
The Deterrence Effects of U.S. Merger Policy Instruments |
0 |
0 |
0 |
32 |
0 |
0 |
1 |
140 |
The Deterrence Effects of U.S. Merger Policy Instruments |
0 |
0 |
0 |
15 |
0 |
0 |
0 |
91 |
The Dynamics of Research Joint Ventures: A Panel Data Analysis |
0 |
0 |
0 |
108 |
0 |
0 |
0 |
374 |
The Dynamics of Research Joint Ventures: A Panel Data Analysis |
0 |
0 |
0 |
96 |
0 |
1 |
1 |
312 |
The Impact of Competition Policy Enforcement on the Functioning of EU Energy Markets |
0 |
0 |
1 |
135 |
1 |
1 |
3 |
129 |
US and EU Secure Vaccine Production on Home Soil |
0 |
0 |
0 |
13 |
0 |
0 |
0 |
50 |
USA und EU setzen auf lokale Impfstoffproduktion - Versorgungssicherheit im Fokus |
0 |
0 |
0 |
3 |
0 |
0 |
0 |
24 |
What Clients Want: Choices between Lawyers' Offerings |
0 |
0 |
0 |
13 |
0 |
1 |
2 |
51 |
What Clients want: Choices between Lawyers' Offerings |
0 |
0 |
0 |
17 |
0 |
0 |
0 |
48 |
What clients want: Choices between lawyers' offerings |
0 |
0 |
0 |
2 |
1 |
1 |
1 |
28 |
Total Working Papers |
2 |
6 |
48 |
3,666 |
19 |
52 |
193 |
10,888 |